Current Report Filing (8-k)
January 19 2023 - 4:44PM
Edgar (US Regulatory)
0001600847
false
00-0000000
0001600847
2023-01-19
2023-01-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d)
of the Securities
Exchange Act of 1934
Date of Report
(Date of earliest event reported): January 19, 2023
Gamida Cell Ltd.
(Exact name of
registrant as specified in its Charter)
Israel |
|
001-38716 |
|
Not
Applicable |
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
116
Huntington Avenue, 7th Floor
Boston, MA |
|
02116 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(617) 892-9080
(Registrant’s
telephone number, including area code)
Not Applicable
(Former name
or former address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered
pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Ordinary Shares, NIS
0.01 par value |
|
GMDA |
|
The Nasdaq Stock Market
LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01
Other Events.
As previously
reported in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, Gamida Cell Ltd. (the “Company”)
was previously engaged in discussions with Lonza Netherlands B.V. (“Lonza”) to terminate that certain Manufacturing Services
Agreement, dated as of June 10, 2019 (the “Manufacturing Agreement”), with Lonza for the manufacture of omidubicel. On December
29, 2022, the Company entered into a settlement agreement (the “Settlement Agreement”) with Lonza pursuant
to which the Company agreed to pay an aggregate amount of €8,000,000 to Lonza in a series of installments, with the first installment
of €1,500,000 paid prior to December 31, 2022 and the final installment payment to be paid no later than September 30, 2024. In
connection with these payments, Lonza and the Company agreed to terminate the Manufacturing Agreement and to a mutual release of any
claims arising out of the Manufacturing Agreement.
Item 9.01 Financial Statements and
Exhibits.
Exhibit
No. |
|
Description |
104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
GAMIDA
CELL LTD. |
|
|
|
January
19, 2023 |
By: |
/s/
Josh Patterson |
|
|
Josh
Patterson |
|
|
General
Counsel |
2
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Apr 2023 to Apr 2024